Who are inhaled Ambisome®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abelcet, Mycostatin, Amphotericin B Deoxycholate, Liposomal Amphotericin B, Amphotericin B Liposome, Group 3: Liposomal amphotericin B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inhaled-ambisome.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

inhaled Ambisome® — Competitive Intelligence Brief

inhaled Ambisome® (inhaled Ambisome®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyene antifungal. Area: Infectious Diseases.

phase 3 Polyene antifungal Sterol component of fungal cell membranes Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

inhaled Ambisome® (inhaled Ambisome®) — Poitiers University Hospital. Amphotericin B, the active component of Ambisome, binds to the sterol component of fungal cell membranes, causing cell lysis and death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
inhaled Ambisome® TARGET	inhaled Ambisome®	Poitiers University Hospital	phase 3	Polyene antifungal	Sterol component of fungal cell membranes
Abelcet	AMPHOTERICIN B	Astellas Pharma	marketed	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Mycostatin	nystatin	Generic (originally Squibb)	marketed	Polyene Antifungal [EPC]	Ergosterol (fungal cell membrane)	1954-01-01
Amphotericin B Deoxycholate	Amphotericin B Deoxycholate	Drugs for Neglected Diseases	marketed	Polyene antifungal	Ergosterol
Liposomal Amphotericin B	Liposomal Amphotericin B	Taiwan Liposome Company	marketed	Polyene antifungal	Ergosterol
Amphotericin B Liposome	Amphotericin B Liposome	Aurobindo Pharma Ltd	marketed	Lipid-based Polyene Antifungal [EPC]
Group 3: Liposomal amphotericin B	Group 3: Liposomal amphotericin B	Fundacion Nacional de Dermatologia	phase 3	Polyene antifungal	Ergosterol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyene antifungal class)

Bharat Serums and Vaccines Limited · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
Dr. Falk Pharma GmbH · 1 drug in this class
Drugs for Neglected Diseases · 1 drug in this class
Federal University of Health Science of Porto Alegre · 1 drug in this class
Fundacion Nacional de Dermatologia · 1 drug in this class
Pfizer · 1 drug in this class
Poitiers University Hospital · 1 drug in this class
Taiwan Liposome Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). inhaled Ambisome® — Competitive Intelligence Brief. https://druglandscape.com/ci/inhaled-ambisome. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab